Mitrix Bio is developing mitochondrial transplantations. In this process, large quantities of lab-grown mitochondria, also known as "mitlets", are introduced into a patient's body. The goal is to boost cellular energy and slow down or reverse aspects of aging.

The company has taken the leap from animal testing to treatments on human volunteers. This includes a 91-year-old patient mentioned in reports on Silicon Valley and longevity.

Previous reports on Mitrix Bio described plans to grow mitochondria from a person's own stem cell tissue and then reintroduce them in large quantities (autologous transplantation) to potentially extend healthspan and even lifespan.

Mitochondrial transplantation has some precedent as an investigational therapy for mitochondrial diseases. Another company, Minovia Therapeutics, is conducting clinical trials with similar approaches for rare mitochondrial disorders.

However, evidence for general longevity or age reversal in relatively healthy older adults is extremely limited. The animal experimental data and mechanistic claims from Mitrix Bio have not yet been broadly published in peer-reviewed journals.

The regulatory framework and details on study design are critical, but not fully transparent. This makes a rigorous risk assessment difficult.

Mitrix Bio leadership has spoken of ambitions to extend the human lifespan to 120 to 130 years. This is based on mouse experiments in which transplanted mitochondria from younger animals improved health and survival.

The underlying idea that mitochondrial dysfunction contributes to aging is scientifically plausible. But translating this into a safe, comprehensive human anti-aging therapy represents a major challenge.

Older patients are vulnerable to adverse events during invasive procedures, especially when the risk profile is poorly characterized. In addition, the participants' dual roles as patients and investors raise questions about conflicts of interest.

Bioethicists warn that selling expensive, poorly validated "longevity" procedures outside of controlled clinical trials could undermine trust in legitimate aging research.